akynzeo
rafa laboratories ltd - netupitant; palonosetron as hydrochloride - capsules - netupitant 300 mg; palonosetron as hydrochloride 0.50 mg - palonosetron, combinations - prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of cancer chemotherapy, including, but not limited to, highly emetogenic chemotherapy.
aloxi- palonosetron hydrochloride injection
mgi pharma - palonosetron hydrochloride (unii: 23310d4i19) (palonosetron - unii:5d06587d6r) - injection - 0.25 mg in 5 ml - aloxi is indicated for: • moderately emetogenic cancer chemotherapy -- prevention of acute and delayed nausea and vomiting associated with initial and repeat courses • highly emetogenic cancer chemotherapy -- prevention of acute nausea and vomiting associated with initial and repeat courses aloxi is indicated for: • prevention of postoperative nausea and vomiting (ponv) for up to 24 hours following surgery. efficacy beyond 24 hours has not been demonstrated. as with other antiemetics, routine prophylaxis is not recommended in patients in whom there is little expectation that nausea and/or vomiting will occur postoperatively. in patients where nausea and vomiting must be avoided during the postoperative period, aloxi is recommended even where the incidence of postoperative nausea and/or vomiting is low. aloxi is contraindicated in patients known to have hypersensitivity to the drug or any of its components. [see adverse reactions (6.2 )] teratogenic effects: category b teratology studies have been perfo
aloxi
helsinn birex pharmaceuticals ltd. - palonosetron hydrochloride - vomiting; cancer - antiemetics and antinauseants, , serotonin (5ht3) antagonists - aloxi is indicated in adults for:the prevention of acute nausea and vomiting associated with highly emetogenic cancer chemotherapy,the prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy.aloxi is indicated in paediatric patients 1 month of age and older for:the prevention of acute nausea and vomiting associated with highly emetogenic cancer chemotherapy and prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy.
palonosetron 0,25 teva solution for injection
teva pharmaceuticals (pty) ltd - solution for injection - not indicated - each vial of 5 ml of solution contains palonosetron (as hydrochloride) 0,25 mg
themiset 75 injection
themis medicare ltd themis medicare ltd 11/12 udyog nagar s.v. road - palonosetron hydrochloride - injection - palonosetron hydrochloride - antiemetics and antinauseants: serotonin (5-ht3)
themiset injection
themis medicare ltd 11/12 udyog nagar s.v road goregaon (w) mumbai - palonosetron hydrochloride - injection - palonosetron hydrochloride 0.250mg/ 5 ml - antiemetics and antinauseants: serotonin (5-ht3)
seacross palonosetron 250 micrograms5ml solution for injection
first pharmaceutical sdn. bhd. - palonosetron (as hydrochloride) -
akynzeo capsule
knight therapeutics inc. - palonosetron (palonosetron hydrochloride); netupitant - capsule - 0.5mg; 300mg - palonosetron (palonosetron hydrochloride) 0.5mg; netupitant 300mg - antiemetics
aloxi solution
knight therapeutics inc. - palonosetron (palonosetron hydrochloride) - solution - 0.25mg - palonosetron (palonosetron hydrochloride) 0.25mg - antiemetics
aloxi capsule
knight therapeutics inc. - palonosetron (palonosetron hydrochloride) - capsule - 0.5mg - palonosetron (palonosetron hydrochloride) 0.5mg - antiemetics